Labcorp Holdings (LH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Labcorp Holdings

NYSE•Healthcare•Diagnostics & Research

$322.73-1.78(-0.01%)After hours

Market Cap

$26.32B

P/E

26.3x

P/S

1.8x

P/B

3.1x

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

How this company scores

GoodMetricSide Score: 74/100

Strongest: Profitability (21/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability21/25

Growth21/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality17/25

Strengths

Rising earningsCash-backed earningsProfit converts from growthConsistent growth

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 26.3x5y range 8.6x – 46.1x

Currently near its 20-quarter median.

P/S · 1.8x5y range 1.1x – 1.8x

Currently near its 20-quarter median.

P/B · 3.1x5y range 1.6x – 3.1x

Price & Volume

Market Cap $26.32B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $14.35B
Q. Revenue: $3.73B
TTM EBITDA: $2.53B
TTM Op. Income: $1.50B
Q. Op. Income: $451.60M
TTM Net Income: $1.00B
Q. Net Income: $298.70M
EPS: $3.66
Shares Out.: $81.70M

$14.35B in TTM revenue grew 6.4% YoY, reaching $3.73B last quarter. TTM EBITDA of $2.53B and TTM operating income of $1.50B show growth is flowing through to the bottom line. TTM net income of $1.00B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 29.8%
EBITDA Margin: 16.9%
Op. Margin: 12.1%
Net Margin: 8.0%

Op. margin of 12.1% is up 0.9% YoY — cost efficiency is improving. Net margin at 8.0% and gross margin of 29.8% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 26.3x
P/S Ratio: 1.8x
P/B Ratio: 3.1x

At 26.3x P/E, the stock trades within typical market levels. P/S of 1.8x and P/B of 3.1x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is down 8% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $18.53B
Cash: $141.80M
Long-Term Debt: $5.86B
Book Value: $8.61B
D/E Ratio: 0.7
Debt/EBITDA: 9.3

With $18.53B in assets and $5.86B in long-term debt, D/E is 0.7and book value is $8.61B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 3 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $445.50M
TTM Free Cash Flow: $1.16B
FCF Margin: 8.1%
FCF / Net Income: 1.2

TTM FCF of $1.16B on $445.50M in operating cash flow. The FCF / Net Income ratio of 1.2x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 8% — a weakening trend.